Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 1
2018 3
2019 2
2020 4
2021 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Fertility preservation in ovarian tumours.
Tomao F, Di Pinto A, Sassu CM, Bardhi E, Di Donato V, Muzii L, Petrella MC, Peccatori FA, Panici PB. Tomao F, et al. Among authors: sassu cm. Ecancermedicalscience. 2018 Dec 6;12:885. doi: 10.3332/ecancer.2018.885. eCollection 2018. Ecancermedicalscience. 2018. PMID: 30679952 Free PMC article. Review.
Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer.
Sassu CM, Palaia I, Boccia SM, Caruso G, Perniola G, Tomao F, Di Donato V, Musella A, Muzii L. Sassu CM, et al. Int J Mol Sci. 2021 Dec 20;22(24):13650. doi: 10.3390/ijms222413650. Int J Mol Sci. 2021. PMID: 34948446 Free PMC article. Review.
Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Musella A, Bardhi E, Marchetti C, Vertechy L, Santangelo G, Sassu C, Tomao F, Rech F, D'Amelio R, Monti M, Palaia I, Muzii L, Benedetti Panici P. Musella A, et al. Among authors: sassu c. Cancer Treat Rev. 2018 May;66:7-14. doi: 10.1016/j.ctrv.2018.03.004. Epub 2018 Mar 23. Cancer Treat Rev. 2018. PMID: 29605737 Review.
First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research.
Tomao F, Boccia SM, Sassu CM, Chirra M, Palaia I, Petrella MC, Di Donato V, Colombo N, Benedetti Panici P. Tomao F, et al. Among authors: sassu cm. Cancer Manag Res. 2020 Jul 7;12:5479-5489. doi: 10.2147/CMAR.S194874. eCollection 2020. Cancer Manag Res. 2020. PMID: 32765062 Free PMC article. Review.
Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
Marchetti C, De Felice F, Boccia S, Sassu C, Di Donato V, Perniola G, Palaia I, Monti M, Muzii L, Tombolini V, Benedetti Panici P. Marchetti C, et al. Among authors: sassu c. Crit Rev Oncol Hematol. 2018 Dec;132:111-115. doi: 10.1016/j.critrevonc.2018.09.018. Epub 2018 Oct 3. Crit Rev Oncol Hematol. 2018. PMID: 30447915 Review.
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB. Tomao F, et al. Among authors: sassu cm. Cancer Treat Rev. 2019 Nov;80:101909. doi: 10.1016/j.ctrv.2019.101909. Epub 2019 Oct 9. Cancer Treat Rev. 2019. PMID: 31629204 Review.
17 results